Publications

Export 94 results:
Author Title Type [ Year(Asc)]
Filters: Author is Serge Gauthier  [Clear All Filters]
2016
Pascoal TA, Mathotaarachchi S, Mohades S, Benedet AL, Chung C-O, Shin M, Wang S, Beaudry T, Kang MS, Soucy J-P et al..  2016.  Amyloid-β and hyperphosphorylated tau synergy drives metabolic decline in preclinical Alzheimer's disease.. Mol Psychiatry.
Ba M, Kong M, Li X, Ng KPin, Rosa-Neto P, Gauthier S.  2016.  Is ApoE ɛ 4 a good biomarker for amyloid pathology in late onset Alzheimer's disease? Transl Neurodegener. 5:20.
Laforce R, Rosa-Neto P, Soucy J-P, Rabinovici GD, Dubois B, Gauthier S.  2016.  Canadian Consensus Guidelines on Use of Amyloid Imaging in Canada: Update and Future Directions from the Specialized Task Force on Amyloid imaging in Canada.. Can J Neurol Sci. 43(4):503-12.
Winblad B, Amouyel P, Andrieu S, Ballard C, Brayne C, Brodaty H, Cedazo-Minguez A, Dubois B, Edvardsson D, Feldman H et al..  2016.  Defeating Alzheimer's disease and other dementias: a priority for European science and society.. Lancet Neurol. 15(5):455-532.
Gordon MForrest, Lenderking WR, Duhig A, Chandler J, J Lundy J, Miller DS, Piault-Louis E, Doody RS, Galasko D, Gauthier S et al..  2016.  Development of a patient-reported outcome instrument to assess complex activities of daily living and interpersonal functioning in persons with mild cognitive impairment: The qualitative research phase.. Alzheimers Dement. 12(1):75-84.
Florian H, Meier A, Gauthier S, Lipschitz S, Lin Y, Tang Q, Othman AA, Robieson WZ, Gault LM.  2016.  Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Study.. J Alzheimers Dis. 51(4):1237-47.
Gauthier S, Feldman HH, Schneider LS, Wilcock GK, Frisoni GB, Hardlund JH, Moebius HJ, Bentham P, Kook KA, Wischik DJ et al..  2016.  Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial.. Lancet. 388(10062):2873-2884.
Gauthier S, Rosa-Neto P, Kass JS.  2016.  Ethical Considerations for the Use of Next-Generation Alzheimer Drugs in Symptomatic and At-Risk Patients.. Continuum (Minneap Minn). 22(2 Dementia):615-8.
Schoemaker D, Buss C, Head K, Sandman CA, Davis EP, Chakravarty MM, Gauthier S, Pruessner JC.  2016.  Hippocampus and amygdala volumes from magnetic resonance images in children: Assessing accuracy of FreeSurfer and FSL against manual segmentation.. Neuroimage. 129:1-14.
Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, Bakardjian H, Benali H, Bertram L, Blennow K et al..  2016.  Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria.. Alzheimers Dement. 12(3):292-323.
Schoemaker D, Poirier J, Escobar S, Gauthier S, Pruessner J.  2016.  Selective familiarity deficits in otherwise cognitively intact aging individuals with genetic risk for Alzheimer's disease.. Alzheimers Dement (Amst). 2:132-9.
Mathotaarachchi S, Wang S, Shin M, Pascoal TA, Benedet AL, Kang MSu, Beaudry T, Fonov VS, Gauthier S, Labbe A et al..  2016.  VoxelStats: A MATLAB Package for Multi-Modal Voxel-Wise Brain Image Analysis.. Front Neuroinform. 10:20.
Gauthier S, Albert M, Fox N, Goedert M, Kivipelto M, Mestre-Ferrandiz J, Middleton LT.  2016.  Why has therapy development for dementia failed in the last two decades? Alzheimers Dement. 12(1):60-4.
2015
Cummings J, Mintzer J, Brodaty H, Sano M, Banerjee S, Devanand DP, Gauthier S, Howard R, Lanctôt K, Lyketsos CG et al..  2015.  Agitation in cognitive disorders: International Psychogeriatric Association provisional consensus clinical and research definition.. Int Psychogeriatr. 27(1):7-17.
Gauthier S, Proaño JVoltaire, Jia J, Froelich L, Vester JChristophe, Doppler E.  2015.  Cerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trials.. Dement Geriatr Cogn Disord. 39(5-6):332-47.
Gauthier S, Rountree S, Finn B, LaPlante B, Weber E, Oltersdorf T.  2015.  Effects of the Acetylcholine Release Agent ST101 with Donepezil in Alzheimer's Disease: A Randomized Phase 2 Study.. J Alzheimers Dis. 48(2):473-81.
Benedet AL, Labbe A, Lemay P, Zimmer ER, Pascoal TA, Leuzy A, Mathotaarachchi S, Mohades S, Shin M, Dionne-Laporte A et al..  2015.  Epistasis analysis links immune cascades and cerebral amyloidosis.. J Neuroinflammation. 12:227.
Zimmer ER, Parent MJ, Leuzy A, Aliaga A, Aliaga A, Moquin L, Schirrmacher ES, Soucy J-P, Skelin I, Gratton A et al..  2015.  Imaging in vivo glutamate fluctuations with [(11)C]ABP688: a GLT-1 challenge with ceftriaxone.. J Cereb Blood Flow Metab. 35(7):1169-74.
Leuzy A, Zimmer ERigon, Dubois J, Pruessner J, Cooperman C, Soucy J-P, Kostikov A, Schirmaccher E, Désautels R, Gauthier S et al..  2015.  In vivo characterization of metabotropic glutamate receptor type 5 abnormalities in behavioral variant FTD.. Brain Struct Funct.
Bier N, Grenier S, Brodeur C, Gauthier S, Gilbert B, Hudon C, Lepage E, Ouellet M-C, Viscogliosi C, Belleville S.  2015.  Measuring the impact of cognitive and psychosocial interventions in persons with mild cognitive impairment with a randomized single-blind controlled trial: rationale and design of the MEMO+ study.. Int Psychogeriatr. 27(3):511-25.
Cloutier S, Chertkow H, Kergoat M-J, Gauthier S, Belleville S.  2015.  Patterns of Cognitive Decline Prior to Dementia in Persons with Mild Cognitive Impairment.. J Alzheimers Dis. 47(4):901-13.

Pages